Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News argenx SE ARGX

argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others.


Recent & Breaking News (NDAQ:ARGX)

argenx announces Annual General Meeting of Shareholders on May 10, 2022

GlobeNewswire March 29, 2022

argenx announces closing of global offering

GlobeNewswire March 28, 2022

argenx raises $700 million in gross proceeds in a global offering

GlobeNewswire March 23, 2022

argenx announces launch of proposed global offering

GlobeNewswire March 22, 2022

argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

Business Wire March 22, 2022

argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire March 3, 2022

argenx to Present at the 42nd Annual Cowen Health Care Conference

GlobeNewswire February 28, 2022

argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022

GlobeNewswire February 24, 2022

argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 10, 2022

argenx Announces VYVGART(TM) Approval in Japan for the Treatment of Generalized Myasthenia Gravis

Business Wire January 20, 2022

argenx Highlights Strategic Priorities for 2022

Business Wire January 7, 2022

argenx to Present at 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2022

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART(TM) (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

GlobeNewswire December 17, 2021

argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART(TM) (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

Business Wire December 17, 2021

argenx to Present at Upcoming Investor Conferences

GlobeNewswire November 10, 2021

argenx Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire October 28, 2021

argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021

GlobeNewswire October 21, 2021

argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings

GlobeNewswire October 8, 2021

argenx to Present at Upcoming Investor Conferences

GlobeNewswire September 3, 2021

argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis

GlobeNewswire August 25, 2021